Who
Cynthia Smith
Director
Company insider
Files Form 4 as: Director, Spero Therapeutics; Director, Agios Pharmaceuticals; Director, Akebia Therapeutics; Director, Protara Therapeutics; Director, Tvardi Therapeutics; Director, Dicerna Pharmaceuticals; Chief Commercial Officer, ZS Pharma.
In numbers
- Trades disclosed
- 99
- Buys
- 1
- Sells
- 1
- Bought
- $53K
- Sold
- $55K
- Companies
- 7
- Companies where not an officer
- 6
- First trade
- 8 Jul 2014
- Last trade
- 23 Jun 2026
- Last filed
- 25 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Jun 2026filed 25 Jun 2026 | SPRO Spero TherapeuticsBiotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 23 Jun 2026filed 25 Jun 2026 | SPRO Spero Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 23 Jun 2026filed 25 Jun 2026 | SPRO Spero Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 23 Jun 2026filed 25 Jun 2026 | SPRO Spero TherapeuticsBiotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —2,816 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,816 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,927 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,816 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,927 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,950 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,950 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —2,816 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —35,700 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | AKBA Akebia Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —53,600 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | AKBA Akebia Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —53,600 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —35,700 at $0.00 | filing |
| 15 Jun 2026filed 16 Jun 2026 | TARA Protara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,000 at $0.00 | filing |
| 15 Jun 2026filed 16 Jun 2026 | TARA Protara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,000 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | TVRD Tvardi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,000 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | TVRD Tvardi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,000 at $0.00 | filing |
News
Analyzing Akebia Therapeutics (NASDAQ:AKBA) and Pharming Group (NASDAQ:PHAR)AKBA · tickerreport.com · 18 Oct 2026Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health ForumAKBA · manilatimes.net · 7 Oct 2026
0 headlines in the last 90 days name Cynthia Smith; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.
Sectors
Related people
Nobody else traded the same names lately.